Tilidine (International)
Scheme
Prop.INN
ATC (Anatomical Therapeutic Chemical Classification)
N02AX01
CAS registry number (Chemical Abstracts Service)
0020380-58-9
Chemical Formula
C17-H23-N-O2
Molecular Weight
273
Therapeutic Category
Opioid analgesic
Chemical Name
3-Cyclohexene-1-carboxylic acid, 2-(dimetylamino)-1-phenyl-, etyl ester, trans-(±)-
Foreign Names
- Tilidinum (Latin)
- Tilidin (German)
- Tilidine (French)
- Tilidina (Spanish)
Generic Names
- Tilidate (OS: BAN)
- Gö 1261 C (Gödecke) (IS)
- W 5759 A (IS)
- Tilidine Hydrochloride (OS: USAN)
- Tilidine Hydrochloride Hemihydrate (PH: BP 2018)
- Tilidine hydrochloride hemihydrate (PH: Ph. Eur. 9)
- Tilidini hydrochloridum hemihydricum (PH: Ph. Eur. 9)
Brand Names
- Valoron
Pfizer, South Africa - Tilicomp beta [+ Naloxone]
Betapharm, Germany - Tilidin AbZ [+ Naloxone]
AbZ-Pharma, Germany - Tilidin AL comp. [+ Naloxone]
Aliud Pharma, Germany - Tilidin comp. STADA [+ Naloxone]
Stada Arzneimittel, Germany - Tilidin comp.-CT [+ Naloxone]
AbZ-Pharma, Germany - Tilidin HEXAL comp [+ Naloxone]
Hexal, Germany - Tilidin N Sandoz [+ Naloxone]
Hexal, Germany - Tilidin retard - 1 A Pharma [+ Naloxone]
1 A Pharma, Germany - Tilidine Sopharma
Sopharma, Bulgaria; Unipharm, Bulgaria - Tilidin-ratiopharm plus [+ Naloxone]
ratiopharm, Germany - Valoron 100mg/ml
Pfizer PFE, Switzerland - Valoron N [+ Naloxone]
Pfizer, Germany - Valtran [+ Naloxone]
Pfizer, Belgium; Pfizer, Luxembourg - Valtran Retard [+ Naloxone]
Pfizer, Belgium - Valtran Retard 100/8 [+ Naloxone]
Pfizer, Luxembourg - Valtran Retard 150/12 [+ Naloxone]
Pfizer, Luxembourg - Valtran Retard 50/4 [+ Naloxone]
Pfizer, Luxembourg - Valoron N retard [+ Naloxone]
Pfizer, Germany
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Prop.INN | Proposed International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.